HomeAbout UsThe TeamTarget Data BaseNews or ReviewsPartners

OncoStem Biotherapeutics                       
Contact Us
About OncoStem Biotherapeutics
OncoStem  Biotherapeutics is an emerging targeted cancer drug discovery firm with ownership of a proprietary oncogene database which allows the identification of vital master cancer genes. Oncostem Bio is  dedicated to the health and welfare of individuals who are living with cancer. 

Interested in learning more?
Committed to a cure for cancer.

OncoStem Biotherapeutics is developing novel targeted cancer therapy. Prior targeted therapies - which include small molecules and biological entities designed  to inhibit what has been thought to be specific and true molecular drivers of cancer - not surprisingly have shown varying degrees of efficacy in certain cancer types. This is a consequence of the ability of cancer cells to reprogram themselves or to become refractory to treatment through the acquisition of new molecular lesions. The problem for cancer patients is compounded by the fact that the mutational profiles of tumors from many cancer patients exclude them as candidates for currently available targeted therapies. By offering patients a broader arsenal of a new class of targeted therapies, we will provide cancer patients with much more effective therapeutic regimens. OncoStem Biotherapeutics is developing novel targeted therapies to the true oncogenic initiators, importantly focusing on those that remain undrugged, a strategy that we believe will dramatically avail cancer patients to more efficacious therapeutic regimens.

To provide solutions to the problem of limited truly personalized targeted drug therapies available to cancer patients, OncoStem Biotherapeutics has developed a Bioinformatics Drug Discovery Platform that utilizes a proprietary algorithm that ranks known cancer initiators, the master drivers, that allows identification of optimal druggable targets. Our lead targets fulfill a set of stringent requirements, including 1) clinical relevance 2) target uniqueness 3) druggability 4) ease of validation 5) commercial attractiveness 6) freedom to operate. They display all the desired characteristics of being true tumor initiators, and master drivers. They are the focus of causative genetic lesions in tumors. They have been demonstrated experimentally and biologically to fulfill the properties of master tumor drivers, as opposed to being bystanders or less important transduction pathway functional partners. Their inhibition suppresses cell growth and/or kills cancer cells that are driven by their presence.  

The Columbia University Small Molecule Core Facility located within the Genome Center, will serve as the primary library screening facility. Our strategy utilizes automated, high-throughput screening of select lead optimized compound libraries available at Columbia and chosen suppliers. Compounds will be screened against OncoStem Biotherapeutics' prioritized target proteins using a fluorescence-based approach. Upon identification of lead compounds, our next steps of drug development will include their detailed functional analysis and biochemical optimization to ensure that our compounds are on target, biologically active, available at desirable dosages and absent of toxicity. We will also initiate the design and development of appropriate companion assays, an area in which OncoStem Biotherapeutics has extensive expertise.

OncoStem Biotherapeutics has partnered with NAL Pharmaceuticals, a specialty drug developer that develops novel dosage forms and proprietary drug delivery systems who intends to enter into a development and commercialization program with OncoStem Biotherapeutics. At New York's new Biospace, we have access to extensive wet laboratory facilities, as well as access to core facilities at New York-based institutions. Our aim is to develop commercially and therapeutically attractive targeted therapies. This will consist of a whole new class of oral, chemical, small molecule drugs against the true oncogenic initiators that serve as the master drivers of cancer, which remain orphan to drug therapies.